Key result
A case of Brugada syndrome with recurrent ventricular tachyarrhythmias did not respond to quinidine therapy, highlighting the challenges in managing non-responders.
Case Report (n=1)
This case report highlights the clinical challenge of managing recurrent ventricular tachyarrhythmias in Brugada syndrome when standard adjunctive quinidine therapy fails.
Quinidine-refractory Brugada VT remains clinically challenging; case report leaves open optimal alternatives for prospective evaluation.
Brugada syndrome is associated with sudden cardiac death in young patients. Currently guidelines recommend the use of implantable cardioverter-defibrillator (ICD) in high-risk patients to prevent sudden cardiac death and adjunctive therapy with quinidine in those who have recurrent ventricular tachyarrhythmias to prevent electrical storm.1,2 Nevertheless, not all patients respond to quinidine, and management of those who do not respond to the therapy is frequently challenging. In this report, we presented the management of a difficult case of Brugada syndrome with recurrent ventricular tachyarrhythmias that did not respond to quinidine therapy.
No takes yet. Share an insight, caveat, or question.
Hai et al. (2016) conducted a case report in Brugada syndrome with recurrent ventricular tachyarrhythmias (n=1). Quinidine was evaluated. A case of Brugada syndrome with recurrent ventricular tachyarrhythmias did not respond to quinidine therapy, highlighting the challenges in managing non-responders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: